RxDoctor Payments Data

Kirk Macnaught, MD

Interventional Cardiology · N Chelmsford, MANPI 1043267636

Payments from drug & device makers

$2,471in general payments, 2019–2025

Across 110 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$555
  • Boston Scientific$277
  • Pfizer$218
  • AstraZeneca$197
  • Amgen$194
  • Johnson & Johnson$126
  • plus $903 from 21 others

What the payments were for

  • Food & beverage$2,471100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,471 in reported general payments places this provider in the 40th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$193,731
Medicare patients
1,327
Services billed
2,602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$162,036
XareltoRivaroxaban86$120,979
EntrestoSacubitril/Valsartan41$45,451
Praluent PenAlirocumab12$14,092
JardianceEmpagliflozin11$11,066
BrilintaTicagrelor13$10,475
Metoprolol Succinate399$8,406
Atorvastatin Calcium327$5,496
Rosuvastatin Calcium79$2,508
Labetalol Hcl23$1,989
Losartan Potassium167$1,832
Ezetimibe39$1,808
ClopidogrelClopidogrel Bisulfate94$1,630
Amlodipine Besylate263$1,603
Valsartan26$1,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$218$162,036127 claims
Johnson & JohnsonXarelto$126$120,97986 claims
NovartisEntresto$555$45,45141 claims
Boehringer IngelheimJardiance$84$11,06611 claims
AstraZenecaBrilinta$197$10,47513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 128 interventional cardiology providers in Massachusetts.

Other interventional cardiology in N Chelmsford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →